Vereos PET/CT

by Philips Medical Systems Nederland B.V.  · Based in Netherlands → — The World's First and Only Fully Digital PET/CT System
Nuclear Medicine Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for pricing
Regulatory Status Disclosed

Overview

The Philips Vereos PET/CT is a groundbreaking medical imaging system, recognized as the world’s first and only fully digital PET/CT solution. It leverages proprietary Digital Photon Counting (DPC) technology, which converts light directly to a digital signal with zero analog noise, overcoming the limitations of conventional photomultiplier technology. This innovation, combined with 1:1 coupling between scintillator elements and DPC detector elements and fast Time-of-Flight (TOF) technology, significantly enhances performance.

The Vereos system offers approximately double the volumetric resolution, sensitivity gain, and quantitative accuracy compared to comparable analog systems. This leads to remarkably clear images, improved detectability and characterization of small lesions, and increased diagnostic confidence. The CT component is based on the Ingenuity CT, featuring 64- or 128-channel capabilities, iDose4 for noise reduction, and optional O-MAR for metal artifact reduction.

Furthermore, the Vereos PET/CT incorporates Artificial Intelligence (AI) through its Adaptive Reconstruction (AR) package, which uses an AI-regularized reconstruction technique to produce images with consistent and reduced noise levels. The system is designed for efficient workflows, faster scans, and reduced PET dose, contributing to an enhanced patient experience. It integrates with Philips IntelliSpace Portal for advanced visualization, review, and analysis.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Digital Photon Counting (DPC) Technology
  • 1:1 Crystal-to-Detector Coupling
  • Fast Time-of-Flight (TOF) Technology
  • 64- or 128-channel CT System
  • iDose4 for Noise Reduction
  • O-MAR (Optional) for Metal Artifact Reduction
  • iPatient Personalized Workflow
  • Adaptive Reconstruction (AR) with AI
  • IntelliSpace Portal Integration for Advanced Visualization
  • Ambient Experience for Patient Comfort

Use Cases

  • Oncology: Detecting, localizing, diagnosing, staging, re-staging cancer
  • Oncology: Monitoring therapy response for various cancers
  • Cardiology: Assessing myocardial perfusion and function
  • Neurology: Diagnosing and monitoring neurological diseases
  • Small lesion detection and characterization
  • Therapy planning and follow-up

What Physicians Need to Know

Key Capabilities
Philips Vereos PET/CT is the world's first and only fully digital PET/CT solution, leveraging proprietary Digital Photon Counting (DPC) technology. This enables improved sensitivity, quantification, and higher-definition imaging, leading to enhanced detectability and characterization of smaller lesions. It significantly reduces scan times, with ultra-fast whole-body scans achievable in as little as two minutes, and allows for lower tracer dose protocols. The system also minimizes motion artifacts and features high timing resolution (310 ps) with Time-of-Flight (TOF) technology. It includes a 64- or 128-channel CT system with iDose4 for noise reduction and optional O-MAR for metal artifact reduction. An AI-powered Adaptive Reconstruction (AR) algorithm further improves low contrast detectability and reduces noise.
Clinical Utility
The system offers improved detectability of small lesions, which is critical for accurate diagnosis, staging, and monitoring of therapy response in oncology, cardiology, and neurology. It enhances diagnostic confidence and provides precise determination of PET activity within the patient. The increased acquisition speed supports new approaches for dynamic imaging and can help identify microscopic disease, potentially altering treatment plans. Faster scans and lower dose contribute to an improved patient experience.
Integration Options
Vereos PET/CT integrates with Philips' IntelliSpace Portal for advanced visualization, review, and analysis. It features the iPatient platform for a patient-centric workflow, designed to reduce clicks and time to results. The CT SyncRight option facilitates communication between the CT system and the injector for optimized contrast dose management. A Web Collaborator tool allows real-time sharing of images and findings with colleagues and referring physicians (not for diagnostic use). The system is built with DICOM conformance.
Compliance Status
The Philips Vereos PET/CT system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). It is compliant with NEMA XR-25 and XR-29 standards for CT Dose Check. The Adaptive Reconstruction (PET AR) algorithm also holds FDA 510(k) clearance as a software application for the Vereos PET/CT system.
Pricing Model
As a high-end medical imaging system, the Philips Vereos PET/CT represents a significant capital expenditure. While specific new system pricing is not publicly detailed, similar 64-slice PET-CT machines can range from $1.5M to $2.5M. Used or refurbished Philips Vereos systems have been listed in the range of $326,000 u2013 $450,000.
User Experience
The system is designed for an enhanced user and patient experience. Fast scans and post-processing capabilities streamline workflow and increase patient throughput. The iPatient platform and ExamCards simplify protocol management, reduce decision points, and promote scan consistency. Philips' Ambient Experience aims to create a positive and comfortable environment for patients. The system features an intelligent user interface with adaptive intelligence for accessible in-context tools.
Support Quality
Philips is noted for its commitment to innovation and provides comprehensive support. Early adopters have reported quick response times from Philips staff, with on-site support often available within a day. The system includes remote monitoring capabilities, and Philips professionals utilize dedicated tools like the Resend Analyzer for issue analysis.
Implementation Complexity
Implementation involves installing complex medical devices and systems, requiring Philips-authorized changes and adherence to government-regulated quality assurance procedures. However, the system is designed for relatively quick readiness, with some facilities reporting it can be operational within days to a week. Turnkey installation services, including site planning and facility modifications, are available from some vendors.
Evidence Base
The Vereos PET/CT is supported by rigorous clinical evidence, including over 100 published clinical studies and more than four years of investigational studies. Clinical trials have demonstrated its ability to perform ultra-fast whole-body scans with consistent image quality and reduced motion artifacts. Studies indicate improved image quality, diagnostic confidence, and accuracy compared to traditional analog PET/CT systems. Its physical performance has been evaluated and found comparable to other state-of-the-art systems according to the NEMA NU2-2012 standard.
Physician Tip

When considering Philips Vereos PET/CT, physicians should leverage its digital photon counting technology for superior small lesion detectability and quantification, especially in oncology, cardiology, and neurology. Utilize the fast scan times and lower dose protocols to enhance patient comfort and throughput. Explore the Adaptive Reconstruction (AR) algorithm for improved image quality and low contrast detectability. The IntelliSpace Portal and Web Collaborator can streamline image review and multidisciplinary collaboration. Be mindful of the system's capabilities for dynamic imaging and its potential to reveal microscopic disease, which can significantly impact treatment strategies. Ensure staff are trained on the iPatient workflow and ExamCards for consistent, efficient operation.

The Vereos PET/CT is designed for seamless integration within a modern imaging department. Its core strength lies in the integrated CT and PET components within a single gantry. It connects with Philips' IntelliSpace Portal for advanced post-processing and visualization. The iPatient platform and ExamCards facilitate workflow integration. While direct EMR integration details were not explicitly found, its DICOM conformance ensures compatibility with PACS and other imaging archives, allowing for efficient data transfer and accessibility across healthcare IT systems. The CT SyncRight option highlights integration with contrast injectors for optimized procedures.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact vendor for pricing
DeploymentOn-premise (physical hardware)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Philips received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its digital PET/CT system in December 2013. The system is a diagnostic imaging device combining PET and CT for detecting, localizing, diagnosing, staging, re-staging, and monitoring therapy response for various diseases in oncology, cardiology, and neurology.
Integrations
EHR Not specified
Specialties Nuclear Medicine, Oncology, Radiology

What the Web Says

The Philips Vereos PET/CT is a fully digital system that has garnered positive attention from physicians and healthcare professionals for its advanced imaging capabilities. It is designed to overcome limitations of traditional analog PET/CT scanners by offering improved image quality, enhanced small lesion detection, and reduced radiation dose and scan times. The system's proprietary Digital Photon Counting (DPC) technology, 1:1 coupling, and digital time-of-flight (TOF) are key innovations contributing to its performance.

Overall: Positive

Strengths

  • Improved image quality and sharpness, with better gray/white-matter contrast in brain imaging.
  • Enhanced small lesion detectability, which can lead to more accurate diagnosis, staging, and treatment monitoring.
  • Reduced radiation dose for patients, technologists, and the public.
  • Shorter scan times, improving patient comfort and increasing patient throughput.
  • More precise quantification and improved volumetric resolution.
  • High system stability across count rate changes and excellent time-of-flight capability.

Limitations

  • Limited data on comparison of digital PET and analog PET in terms of image quality and diagnostic confidence in patients.
  • DLP (dose-length product) calculation differs in digital scanners compared to analog, which can complicate retrospective study comparisons.
  • Subjective image quality assessment can be influenced by personal preference.
  • A similar study on activity optimization for Vereos PET/CT has not been conducted, unlike for other digital PET/CT systems.
  • Single-institution studies limit the generalizability of some findings.

Based on reviews from: Journal of Nuclear Medicine, YouTube (Philips Healthcare testimonials), PR Newswire UK (Frost & Sullivan), Philips (Case study, product information), Applied Radiology, PMC (PubMed Central), Saludiario

Last updated: 2026-07-19

Ratings & Reviews

Rate Vereos PET/CT

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

UR Medicine
UR Medicine Introduces Digital PET/CT Technology at Outpatient Imaging Center
UR Medicine has implemented Upstate New York's first digital PET/CT system, the Philips Vereos, which provides higher quality images faster, more safely, and comfortably, aiding physicians in diagnosis and treatment evaluations.
2018-04
Journal of Nuclear Medicine
Performance Evaluation of the Vereos PET/CT System According to the NEMA NU2-2012 Standard
This study evaluates the physical performance of the Philips Vereos whole-body PET/CT system against the NEMA NU2-2012 standard, demonstrating its comparable performance to other state-of-the-art systems, with a peak noise-equivalent count rate occurring at a higher activity concentration.
2019-04
Journal of Nuclear Medicine
Evaluation of digital PET imaging Vereos PET/CT
This article educates the nuclear medicine community on the differences between digital and analog PET/CT systems, highlighting the advantages of the Philips Vereos PET/CT in producing high-quality images with better small lesion detection, reduced radiation dose, and shorter scan times.
2019-05
BfArM (Federal Institute for Drugs and Medical Devices, Germany)
URGENT - Field Safety Notice Medical Device Correction - BfArM
This Field Safety Notice addresses a detected problem in the Philips Vereos PET/CT system that could pose a risk to patients or users, indicating a medical device correction.
2019-06
Applied Radiology
Vereos PET/CT: Leveraging Digital Precision for Innovative Approaches | Applied Radiology
This article discusses how the Philips Vereos digital PET/CT is being used in initiatives to achieve high-quality images at low doses and fast acquisition times, with research supporting ultra-fast whole-body PET/CT scans in as little as two minutes.
2019-11
RT Imaging
World's Most Advanced PET/CT Scan System Installed in Honolulu
InSight Imaging in Honolulu installed a Philips Vereos PET/CT system, the world's first fully digital PET/CT, offering improved detectability of small lesions, reduced PET dose, and faster scan times for cancer, cardiology, and brain imaging.
2019-10
accessdata.fda.gov
Philips Medical Systems Nederland B.V. May 19, 2021 Nimit Shah Regulatory Specialist Veenpluis 4-6 Best, 5684 PC NETHERLAND
This FDA 510(k) premarket notification details the substantial equivalence of the Vereos PET/CT system to a predicate device, outlining its diagnostic imaging capabilities for various diseases in oncology, cardiology, and neurology.
2021-05
accessdata.fda.gov
Philips Medical Systems Nederland B.V. August 6, 2021 Carmit Shmuel Regulatory Affairs Specialist Veenpluis 6 Best, 5684 PC
This FDA 510(k) premarket notification addresses the addition of a new optional Adaptive Reconstruction software application to the Vereos PET/CT system, demonstrating its safety and effectiveness through non-clinical performance tests.
2021-08

Videos

Product demos, reviews, and walkthroughs for Vereos PET/CT.

Loading videos...

View all on YouTube

Frequently Asked Questions

The AI in Vereos PET/CT, particularly its Proactive Intelligence, leverages deep learning to improve image reconstruction, reduce noise, and enhance lesion detectability. This leads to clearer images, more consistent quantification, and potentially earlier and more confident diagnoses.
The AI components of Vereos PET/CT adhere to stringent regulatory standards, including FDA clearance and CE marking, where applicable. Data security is paramount, with measures like encryption, access controls, and compliance with HIPAA and GDPR guidelines to protect patient information.
Vereos PET/CT's AI focuses on quantitative accuracy and workflow automation, utilizing its digital photon counting technology to provide highly reproducible results. This allows for precise treatment response assessment and streamlined operations compared to analog or less integrated digital systems.
While advanced AI features contribute to the system's overall value, Philips aims to integrate these capabilities efficiently. The total cost includes the initial investment, potential for improved throughput and reduced scan times, and ongoing software maintenance and upgrade subscriptions.
While powerful, the AI in Vereos PET/CT primarily assists with image processing, quantification, and workflow optimization, not autonomous diagnosis. Clinical interpretation still requires expert physician oversight, and the AI's performance may vary in extremely rare or atypical pathologies.
Philips provides comprehensive training programs for clinical and technical staff to ensure optimal utilization of the AI features. The system is designed for seamless integration with existing PACS/RIS via standard protocols like DICOM, minimizing IT overhead.

Related Tools

Visiopharm AI-driven Precision Pathology
Visiopharm
Oncology AI
Visiopharm provides AI-driven precision pathology software for research and diagnostics, offering image analysis applications for metastasis detection and biomarker evaluation.
DeepHeme
Memorial Sloan Kettering Cancer Center (developed in collaboration with UCSF and UC Berkeley)
Lab & Diagnostics
DeepHeme is an AI tool developed by Memorial Sloan Kettering Cancer Center, UCSF, and UC Berkeley that automates the counting and classification of blood and bone marrow cells to assist in the diagnosis of blood cancers, reducing manual review time and achieving expert-level accuracy.
ScreenPoint Medical
ScreenPoint Medical
Clinical Decision Support & Reference
ScreenPoint Medical offers Transpara, an AI-powered solution for breast cancer detection and diagnosis in mammography and digital breast tomosynthesis, designed to assist radiologists.
INIFY Prostate
ContextVision
Clinical Decision Support & Reference
INIFY Prostate is an AI-based decision support tool that accurately outlines suspicious prostate cancer areas in digitalized prostate biopsy samples.
Cartesion Prime (PCD-1000A/3) V10.21
Canon Medical Systems USA, Inc.
Clinical Decision Support & Reference
The Cartesion Prime (PCD-1000A/3) V10.21 is a premium, air-cooled digital PET/CT scanner from Canon Medical Systems, featuring AI-assisted deep learning reconstruction (AiCE) for superior image quality, faster scans, and reduced dose.
DERM (by Skin Analytics)
Skin Analytics
Clinical Decision Support & Reference
DERM is an AI as a Medical Device (AIaMD) with Class III CE mark that assesses dermoscopic images of skin lesions to provide a suspected diagnosis and referral recommendation, aiming to triage patients and reduce waiting times for skin cancer assessment.

See all Oncology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.